Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis Interventions: Drug: REGN2477+REGN1033; Drug: Matching placebo Sponsor: Regeneron Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Inclusion-Body Myositis | Research